DIP Episode 136 - Comprehensive USMLE Step 1 Immunology Review 1

Source / episode info

• Episode: 136
• Title: Divine Intervention Episode 136 – Comprehensive USMLE Step 1 Immunology Review 1
• Published: 2019-08-19
• Source: Episode page

One-liner

This episode provides a comprehensive review of immunology, covering the fundamental differences between innate and adaptive immunity, detailing the three complement pathways and their regulatory proteins (CD55, CD59), and reviewing cytokine-driven hematopoiesis for various blood cell lineages.

High-yield summary

• Innate vs. Adaptive: The innate system is hardwired/heritable and recognizes general PAM Ps (e.g., LPS); the adaptive system is acquired through exposure or vaccination, providing specific memory.
• Complement Regulation: Complement proteins are tightly controlled by surface molecules: CD55 (Decay Accelerating Factor) prevents {C}3 convertase formation; CD59 prevents MAC assembly ({C}9).
• PNH Pathophysiology: A mutation in the PIGA gene impairs GPI anchor synthesis, leading to the loss of CD55 and CD59 on red blood cells (RB Cs), resulting in uncontrolled complement lysis.
• Cytokine Lineage Specificity: Myeloid lineage requires factors like G-CSF or GM-CSF; Lymphoid lineage maturation is supported by IL-7.
• Hematopoiesis Analogs: Chronic kidney disease anemia (EPO deficiency) can be treated with EPO analogs (Darbepoetin); ITP can be managed with TPO agonists (Romiplostim) or receptor agonists (L-thrombopag).

Learning objectives

• Differentiate the molecular and functional differences between innate and adaptive immune responses.
• Describe the three complement pathways and identify key regulatory proteins (\text{CD}55, \text{CD}59).
• Trace the cytokine signaling required for the differentiation of myeloid (e.g., granulocytes, erythrocytes) and lymphoid lineages.
• Recognize the clinical manifestations and management strategies for primary deficiencies in hematopoiesis or complement regulation (PNH, ITP).
• Understand the relationship between kidney function/malignancy and erythropoietin levels.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Myeloid vs. Lymphoid Lineage Cytokines

Management pearls

• PNH Management: The primary goal is to prevent complement attack on the RBC membrane. Use C5 inhibitors (Eculizumab) or complement regulators (e.g., plasma exchange). Always vaccinate before starting \text{C}5 inhibition.
• CKD Anemia: Treat with ES As (e.g., Darbepoetin) to replace deficient endogenous \text{EPO}. Monitor iron stores and administer erythropoietin before the patient is transfused, if possible.
• ITP Management: First-line treatment often involves corticosteroids or IVIG; for refractory cases, TPO analogs (Romiplostim) are used to stimulate platelet production.
• Complement Deficiency Workup: If recurrent infections suggest terminal complement deficiency (e.g., Neisseria), testing for \text{C}5\text{b}-9 or specific components is warranted.

Don't miss

Integration & clinical reasoning

• Immunology & Genetics: The PNH disorder provides a perfect link between genetics (PIGA mutation) and immunology (complement dysregulation).
• Hematology & Endocrinology: CKD anemia links renal function (EPO production) to hematopoiesis, while tumor secretion of \text{EPO} links endocrinology/oncology to polycythemia.
• Immunopharmacology: The use of monoclonal antibodies like Eculizumab demonstrates how targeted drug therapy can modulate specific components of the immune cascade (\text{C}5).

Concept connections / cross-references

• For a deeper dive into general immunology and cell signaling, review [Episode 134].
• For detailed information on hematologic disorders and bone marrow function, see [Episode 120].

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• Pattern: Recurrent Meningitis + Thrombosis: Points strongly to PNH due to complement dysregulation (\text{CD}55/\text{CD}59 loss). Next step is prophylactic vaccination before \text{C}5 inhibitor therapy.
• Pattern: Isolated Thrombocytopenia in SLE/Lupus: Suggests ITP, an autoimmune process targeting platelet components. Management involves TPO stimulation (Romiplostim).
• Pattern: Anemia with CKD or Tumor Mass: Points to \text{EPO} dysregulation. If the cause is kidney failure, it's deficiency; if the source is a tumor (e.g., RCC), it's excess/ectopic production.

Test yourself

Common mistakes to avoid

Common traps

OMM / COMLEX integration

• Autonomic Nervous System Drug Targets: Systemic pharmacologic agents alter sympathetic and parasympathetic balance. Anticholinergic drugs (atropine, diphenhydramine) paralyze parasympathetic outflow from the vagus and pelvic splanchnics (urinary retention, ileus), while cholinergic agents (organophosphates, pyridostigmine) produce profound parasympathomimetic overactivation.
• Viscerosomatic Manifestations of Drug Toxicity: Drug-induced hepatotoxicity (acetaminophen, methotrexate) triggers acute tissue texture changes at right T5–T9 paraspinal tissues. Drug-induced interstitial nephritis (NSAIDs, penicillins) manifests at T10–L1.
• Detoxification & Lymphatics: Renal and hepatic clearance of pharmacologic metabolites is enhanced by maintaining thoracic inlet patency, ensuring unimpeded thoracic duct drainage into the left subclavian vein.